Theravance Biopharma Stock Investor Sentiment
| TBPH Stock | USD 9.47 0.14 1.46% |
Under 70% of Theravance Biopharma's investor base is looking to short. The analysis of overall sentiment of trading Theravance Biopharma stock suggests that many investors are alarmed at this time. Theravance Biopharma's investing sentiment shows overall attitude of investors towards Theravance Biopharma.
Theravance |
Theravance Biopharma Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Theravance Biopharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Theravance Biopharma that are available to investors today. That information is available publicly through Theravance media outlets and privately through word of mouth or via Theravance internal channels. However, regardless of the origin, that massive amount of Theravance data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Theravance Biopharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Theravance Biopharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Theravance Biopharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Theravance Biopharma alpha.
Theravance Biopharma Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Theravance Bio Up 2.2 percent Since Last Earnings Report Can It Continue | 09/04/2024 |
2 | Theravance Biopharma Receives Buy Rating from HC Wainwright | 09/16/2024 |
3 | Theravance Biopharma, Inc. Receives 13.75 Consensus PT from Analysts | 10/02/2024 |
4 | Acquisition by Winningham Rick E of 3252 shares of Theravance Biopharma at 7.83 subject to Rule 16b-3 | 10/11/2024 |
5 | Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024 | 10/24/2024 |
6 | PTC Therapeutics Reports Q3 Loss, Tops Revenue Estimates | 11/07/2024 |
7 | Theravance Biopharma GAAP EPS of -0.26 misses by 0.03, revenue of 16.87M beats by 1.45M | 11/12/2024 |
8 | Theravance Biopharma Inc Q3 2024 Earnings Call Highlights Strong Sales Growth and ... | 11/13/2024 |
9 | Theravance Biopharma Third Quarter 2024 Earnings Revenues Beat Expectations, EPS Lags | 11/14/2024 |
10 | Insider Trading | 11/19/2024 |
11 | Disposition of 9178 shares by Rhonda Farnum of Theravance Biopharma at 9.97 subject to Rule 16b-3 | 11/20/2024 |
Complementary Tools for Theravance Stock analysis
When running Theravance Biopharma's price analysis, check to measure Theravance Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theravance Biopharma is operating at the current time. Most of Theravance Biopharma's value examination focuses on studying past and present price action to predict the probability of Theravance Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theravance Biopharma's price. Additionally, you may evaluate how the addition of Theravance Biopharma to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |